Administration of pharmacological FoxO1 inhibitor ameliorated type 1 diabetes‐induced vascular remodelling through decreasing the expression of pro‐inflammatory factors, NLRP3 inflammasome activation, adhesion factors, MMPs and apoptosis, reversing the SMCs phenotypic switching. The gene discussed is FOXO1; the disease is type 1 diabetes mellitus.